--- title: "Creatv 宣布将在 2026 年美国临床肿瘤学会（ASCO）会议上进行五项临床数据展示" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/285223983.md" description: "Creatv Bio 是一家癌症诊断血液检测公司，宣布将在 2026 年美国临床肿瘤学会（ASCO）年会上进行一场海报展示和四个海报摘要，会议定于 2026 年 5 月 29 日至 6 月 2 日在芝加哥举行。展示内容包括关于血液生物标志物在预测转移性乳腺癌无进展生存期方面的研究，以及与制药合作伙伴合作使用 LifeTracDx®血液检测的研究。该公司旨在开发癌症治疗的诊断工具，并提供持续监测以优化治疗方案" datetime: "2026-05-05T14:20:33.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285223983.md) - [en](https://longbridge.com/en/news/285223983.md) - [zh-HK](https://longbridge.com/zh-HK/news/285223983.md) --- # Creatv 宣布将在 2026 年美国临床肿瘤学会（ASCO）会议上进行五项临床数据展示 MONMOUTH JUNCTION, N.J., May 5, 2026 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, is pleased to announce one poster presentation and four poster abstracts in conjunction with it's pharmaceutical company collaborators at the upcoming 2026 ASCO Annual Meeting, May 29-June 2, 2026, McCormick Place, Chicago, Illinois. **Abstract Title:** Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis. **Abstract:** 2652 **Session Title:** Developmental Therapeutics—Immunotherapy **Poster Board:** 442 **Date and Time:** May 30, 2026, 1:30 PM – 4:30 PM CDT **_Poster Abstracts in Collaboration with BriaCell, a_** **_clinical-stage immuno-oncology drug company,_** **Abstract Title:** Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors. **Abstract:** e14535 **Abstract Title:** Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy. **Abstract:** e15525 **_Poster Abstracts in Collaboration with CytoDyn, a biotechnology company developing innovative treatments for cancer._** **Abstract Title:** Safety and 5-year survival following treatment with leronlimab plus physician's choice combination therapy in patients with metastatic triple-negative breast cancer. **Abstract:** e14535 **Abstract Title:** Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study. **Abstract:** e13109 Creatv Bio's LifeTracDx® blood test, described in the abstracts above, was used in the various studies to rapidly develop companion/complementary diagnostic tools for specific cancer therapies and provided continuous monitoring of cancer patients for pharmaceutical companies to optimize therapy regimes. **About Creatv Bio** Creatv Bio is a CLIA-certified cancer diagnostics company providing laboratory testing services to pharmaceutical and research partners, as well as to patients for research and investigational purposes. The LifeTracDx® blood test is an analytically validated assay under ongoing research and development. Current research applications include evaluation of circulating biomarkers in oncology to support translational and exploratory studies. The assay is intended for research and investigational use only and is not intended for use in clinical diagnosis, prognosis, treatment selection, or disease monitoring. For our research studies and complete listing of peer-reviewed publications and scientific posters, please visit our website at creatvbio.com. **Creatv contacts**: **Daniel L Adams** **Ron Baker** Chief Scientific Officer Chief Business Officer dan@creatvmicrotech.com ron@creatvmicrotech.com 732-783-7132 (office) 301-785-5185 (mobile) View original content to download multimedia:https://www.prnewswire.com/news-releases/creatv-announces-five-clinical-data-presentations-at-asco-2026-302762698.html SOURCE Creatv MicroTech, Inc. ### 相关股票 - [SONN.CVR.US](https://longbridge.com/zh-CN/quote/SONN.CVR.US.md) - [MBIO.US](https://longbridge.com/zh-CN/quote/MBIO.US.md) - [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md) - [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md) - [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md) - [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md) - [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md) - [BCTX.US](https://longbridge.com/zh-CN/quote/BCTX.US.md) - [BCTXZ.US](https://longbridge.com/zh-CN/quote/BCTXZ.US.md) - [BCTXW.US](https://longbridge.com/zh-CN/quote/BCTXW.US.md) - [CYDY.US](https://longbridge.com/zh-CN/quote/CYDY.US.md) - [BCTXL.US](https://longbridge.com/zh-CN/quote/BCTXL.US.md) ## 相关资讯与研究 - [瑞银上调爵士制药评级：核心业务韧性强劲，新药 Ziihera 成增长引擎](https://longbridge.com/zh-CN/news/286920691.md) - [Tevogen Bio Q1 运营亏损收窄 48%，推进 AI 平台与细胞疗法管线](https://longbridge.com/zh-CN/news/287086570.md) - [制药巨头集体拥抱 AI 智能体：百时美施贵宝向 3 万员工推广 Claude](https://longbridge.com/zh-CN/news/287074661.md) - [CAR-T 迎接新时代](https://longbridge.com/zh-CN/news/286999381.md) - [创胜集团医药-B 合作伙伴 INHIBRX 报告 OZEKIBART 的 CRC 最新积极数据并宣布就治疗软骨肉瘤提交美国 BLA 申请](https://longbridge.com/zh-CN/news/287126678.md)